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ABSTRACT We report here results of clinical trials on a
birth control vaccine, consisting ofa heterospecies dimer of the
.3 subunit of human chorionic gonadotropin (hCG) associated
noncovalently with the a subunit of ovine luteinizing hormone
and coijugated to tetanus and diphtheria toxoids as carriers,
that induces antibodies of high avidity (Ka 1010 M-) against
hCG. Fertile women exposed to conception over 1224 cycles
recorded only one pregnancy at antibody titers of >50 ng/ml
(hCG bioneutralization capacity). The antibody response de-
clines with time; fertility was regained when titers fell to <35
ng/ml. This study presents evidence of the feasibility of a
vaccine for control of human fertility.
A number of contraceptive methods are available; they do
not, however, suit all potential users. There is need to
develop additional methods, in particular those that are
reversible, require only periodic intake, and do not disturb
menstrual regularity or bleeding. Vaccines regulating fertility
offer promising prospects to meet these specifications. The
rationale for these vaccines is to induce the formation of
antibodies and/or cell-mediated immunity to intercept selec-
tively a process critical to the success of reproduction. A
number of potential antigens are being investigated (1-7).
Among these are hormones, which play an important role in
the regulation of fertility. Human chorionic gonadotropin
(hCG) is an early signal of conception and is considered
essential for establishment and maintenance of early preg-
nancy. An advantage in choosing hCG as a target for immu-
nocontraception is that its inactivation would not interfere
with other physiological processes in the female, such as
ovulation and production of sex steroid hormones.
Carrier conjugation with tetanus toxoid (TT) was proposed
as a strategy to overcome the immunological tolerance of a
woman against hCG (8). This initial prototype vaccine
(/3hCG-TT adsorbed on alum) had limitations. It induced high
antibody titers in only a small percentage of women, and
those with low titers were not protected from pregnancy (9).
Three changes were made to enhance immunogenicity.
(i) An adjuvant, the sodium phthalyl derivative of lipo-
polysaccharide, was included in the first injection. This
nonpyrogenic adjuvant is usable in aqueous phase (10). Its
use doubled, on average, anti-hCG titers and increased the
frequency of high responders.
(ii) The intrinsic immunogenicity of (3hCG was enhanced
by associating it noncovalently with the a subunit of ovine
luteinizing hormone (LH) to form a heterospecies dimer
(HSD), a laboratory-made hormone that attains a conforma-
tion which recognizes receptors on target tissues (whereas
isolated subunits do not) and generates a steroidogenic re-
sponse even superior to that by hCG (11). HSD linked to
carriers was indeed found to be more immunogenic than
,8hCG in rats and monkeys (12). Moreover, the antibodies
had better capacity to neutralize the bioactivity of hCG (11,
13).
(iii) HSD was conjugated to one of two different carriers,
TT or diphtheria toxoid (DT); these conjugates were used in
an alternating sequence. This schedule was adopted since
carrier-induced immunosuppression, observed in a small
percentage of women on repeated injection of conjugates
with the same carrier, could be overcome by presenting the
hormonal subunit on an alternate carrier (14).
After preclinical toxicology studies, ethical and drug reg-
ulatory agency approvals, phase I clinical trials were under-
taken with the HSD vaccine in five institutions in India.
Volunteers were women who had previously undergone
elective tubal ligation. The vaccine was able to induce
anti-hCG antibodies in all women (15). The response was
reversible. Ovulation and menstrual regularity were unaf-
fected and the duration and amount of bleeding were normal
(16). A careful study of 36 hematological, biochemical, met-
abolic, and endocrinological parameters in the immunized
women revealed no significant side effects (17). Similar
results had earlier been obtained in trials carried out with the
(3hCG-TT vaccine in 16 women at Helsinki, Uppsala, Bahia,
and Santiago under the auspices of the International Com-
mittee for Contraception Research ofthe Population Council,
New York (18).
It was important to determine whether the antibodies
induced by the HSD- and 8hCG-based vaccines in monkeys
and in women (phase I clinical trials) had any reactivity with
somatic tissues. Immunopathological studies demonstrated
the lack of nuclear, DNA, parietal cell, smooth muscle, islet
cell, adrenal cortex, thyroid mitochondrial, thyroglobulin,
C-reactive protein, and rheumatoid factor reactivities (19).
Chronic toxicology studies have also been carried out in
monkeys that were hyperimmunized for 7 years with an
analogous vaccine inducing antibodies against both monkey
CG and LH. No significant immunopathology was observed
in any organ, including the pituitary and the kidney (20, 21).
Moreover, women immunized with the vaccine in 1977-1978
during phase I clinical trials did not manifest any symptoms
ofautoimmune disease nor did their sera have reactivity with
human and primate somatic tissues. Nevertheless, the po-
tential for tissue cross-reactivity needs to be considered as
vaccine development proceeds.
The objective ofthe present trial was to determine whether
a vaccine based on the heterospecies dimer of the a subunit
ofovine LH and I8hCG can prevent pregnancy in women and,
if so, to determine the level of antibody titers necessary for
efficacy.
Abbreviations: hCG, human chorionic gonadotropin; LH, luteinizing
hormone; HSD, heterospecies dimer of a subunit of ovine LH and
hi subunit of hCG; TT, tetanus toxoid; DT, diphtheria toxoid.
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MATERIALS AND METHODS
Vaccine. The improved vaccine is HSD coupled to either
TT or DT. HSD was generated by incubating equimolar
concentrations of /3hCG and the a subunit of ovine LH in 10
mM phosphate buffer (pH 7.2) at 370C for 24 hr as described
(11). Conjugation of HSD with carriers was carried out as
described (14, 15). The first injection contained 150 Ug each
of HSD-TT and HSD-DT adsorbed on alum, along with 1.0
mg of the sodium phthalyl derivative of lipopolysaccharide.
Subsequent injections were with 300 pg of HSD-TT or
HSD-DT adsorbed on alum in an alternating sequence.
Study Protocol and Procedures. The trials were conducted
at the All India Institute of Medical Sciences, and Safdarjung
Hospital, New Delhi; and Postgraduate Institute of Medical
Education and Research, Chandigarh. Approvals of the
Drugs Controller of India and institutional ethics committees
were obtained. Women attending the family planning clinics
in these institutions were enrolled for the study after provid-
ing informed, written consent. They were ofreproductive age
(20-35 years), had an active sexual life, and reported having
regular menstrual cycles. All volunteers had at least two
living children. Blood samples on days 18 and 24 of two
preimmunization cycles were analyzed for progesterone lev-
els to confirm ovulation; these ranged from 16 to 51 nM.
Women in whom pregnancy was suspected or who were
breast-feeding were not included in the trial. In addition,
women who had histories of recurrent abortions; secondary
infertility; or allergic, autoimmune, or endocrine disorders
were also excluded, as were women with known or suspected
malignancies.
Immunization consisted of three primary injections of the
vaccine at 6-week intervals. Booster injections were given
subsequently as and when necessary in order to maintain
antibody titers above 50 ng/ml (hCG bioneutralization ca-
pacity) to those desiring to continue in the study. Subjects
were required to report to the clinic for follow-up in the 1st
and 3rd week of each cycle. Blood was withdrawn on each
visit and sent to the National Institute of Immunology for
determination of antibody titers.
The neutralization capacity of antibodies was estimated
by a modification of a receptor binding inhibition assay
described earlier (13). Briefly, testes of 2- to 3-month-old
Wistar outbred rats were decapsulated and homogenized in
a Polytron homogenizer in 50 mM Tris HCl buffer (pH 7.4)
containing 5 mM MgCl2, 0.1% bovine serum albumin, and
0.1% sodium azide. The homogenate was filtered through a
nylon mesh and centrifuged at 500 x g for 10 min at 40C. The
resulting pellet was resuspended in 8 ml of Tris buffer per
pair of testes; 50 ,ul of testicular homogenate was incubated
with 100 ul of various dilutions of human sera and 1 ng of
125I-labeled hCG (125I-hCG) (8-12 ,uCi/,ug; 1 Ci = 37 GBq)
for 2 hr at 37°C. The assay was terminated by the addition
of 1 ml of cold Tris buffer. Tubes were centrifuged at 2000
x g; the resulting pellet was washed with Tris buffer and
assayed for radioactivity. Dilutions of sera causing a 50%
inhibition in the binding of 125I-hCG were computed by
regression analysis. Bioneutralization capacity was ex-
pressed in ng per ml of serum. The avidity of antibodies for
hCG was determined by the cold displacement method
essentially as described (15). Briefly, diluted antisera were
incubated with labeled hCG in the presence of increasing
amounts of unlabeled hCG at 4°C for 24 hr. Bound fractions
precipitated by 12.5% PEG 8000 were separated by cen-
trifugation at 1500 x g for 20 min and assayed in an LKB
multi-y-counter. Association constants were computed by
nonlinear regression analysis. Cross-reactivity of antisera
with human thyroid-stimulating hormone, human follicle-
stimulating hormone, and human LH was determined by
direct binding assays (15). Progesterone levels in luteal
phase blood samples were estimated by RIA, using reagents
supplied by the World Health Organization Matched Re-
agents Program. Menstrual records and follow-up forms
were sent every month to the National Institute of Immu-
nology and Indian Council of Medical Research.
An antibody level of 50 ng/ml (hCG bioneutralization
capacity) was fixed as the putative threshold for testing
efficacy. For 95% confidence, observations were to be made
for at least 750 cycles. Alternative contraception (intrauterine
devices or condoms) was prescribed until antibody titers
above the threshold were attained, after which all alternative
methods were terminated. Results were conveyed to the
respective centers within 1 week. In the event of antibody
titers declining below 50 ng/ml, subjects had the option of
taking a booster injection or withdrawing from the trial. In the
latter case, they were followed up until antibody titers
declined to levels near 0. In case the cycle was delayed, a
pregnancy test was conducted and if pregnancy was con-
firmed, medical termination was offered by the clinics free of
cost, but the option of continuing or terminating the preg-
nancy was left to the woman.
RESULTS
Of 162 women interviewed, 148 completed the schedule of
three primary injections. While all women made antibodies
to hCG, 119 (80%) generated titers that were clearly >50
ng/ml. On March 31, 1992, observations were completed on
750 cycles when enrollment was stopped and booster in-jections were withheld unless specifically requested by the
subjects, in accordance with trial conditions approved by
institutional ethics committees. Follow-up was continued
on women with circulating antibodies. As ofAugust 1, 1993,
observations had been recorded on 1224 cycles. One preg-
nancy had occurred in a woman having an antibody titer of
>50 ng/ml (the pregnancy was terminated by vacuum
aspiration upon the subject's request). Fig. 1 gives the
kinetics of antibody response and period of protection in
four representative women. Booster injections to those
willing to continue in the study were given at an average of
3 months. Eight women had completed >30 cycles without
becoming pregnant, 9 had completed 24-29 cycles, 12
completed 18-23 cycles, 15 completed 12-17 cycles, and 21
subjects had completed 6-11 cycles of continuous exposure
to the risk of pregnancy. Twenty-six pregnancies occurred
among participants who had titers below the level of 50
ng/ml and who had not used alternative contraceptives
effectively (see below).
The antibodies had high affinity for hCG (Ka 1010 M-1)
and could inactivate hCG bioactivity in vitro and in vivo.
Cross-reactivity ofthe antibodies to human LH ranged from
10% to 75%, but antibodies were totally devoid of cross-
reactivity with human follicle-stimulating hormone and
human thyroid-stimulating hormone. Immunization did not
change the menstrual regularity; 85% of the cycles were
within the normal range (22-35 days). Longer and shorter
cycles occurred with similar frequencies in women with
antibody titers of >50 ng/ml and in those with titers of <35
ng/ml (Fig. 2), a level at which women could conceive in the
absence of alternative contraception. This is consistent
with a previous study in which no relationship was seen
between the degree of cross-reactivity with human LH and
menstrual length (16). Luteal progesterone, estimated in
single 3rd-week serum samples, ranged between 14 and 44
nM in ==80% of the cycles. These levels are indicative of
ovulation.
Reversibility. The response to the vaccine was reversible;
antibody titers declined in all cases in the absence of booster
injections. Although alternative contraceptives were pro-
vided, some women became pregnant when antibody titers
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FIG. 1. Kinetics of anti-hCG response in four subjects after immunization with the HSD vaccine. All subjects (MRG, HJN, TRW, SVN;
30, 32, 23, and 29 years old) were of proven fertility with two live children (P2); HJN and SVN had also undergone elective termination of an
unwanted pregnancy (P2+1). Arrows denote injections with the vaccine at a gonadotropin dose of300 Ag. Rectangles near the top abscissa indicate
menstrual events. Periods denoted by solid bars represent cycles in which the woman was exposed to the risk of pregnancy.
were <35 ng/ml. Fig. 3 depicts the case of a subject who,
after being protected for 12 cycles, conceived when her
antibody titers were <5 ng/ml. Four other women, who
conceived at antibody titers of <5, <5, 10, and 20 ng/ml,
respectively, carried their pregnancies to term and delivered
normal offspring. Ofthe remaining pregnancies that occurred
during periods of low titers, or due to nonadministration of
the booster injection, 12 took place at titers at or <20 ng/ml
and 9 were between 21 and 35 ng/ml (Table 1). No late
abortions were observed.
DISCUSSION
The present study provides evidence for prevention of preg-
nancy in women by circulating anti-hCG antibodies. The anti-
bodies have to be directed against determinants that ensure
bioneutralization of the hormone. Levels of >50 ng/ml are
A V
Menstrual cycle length, days
FIG. 2. Regularity of menstrual cycles in women carrying anti-
hCG antibodies of >50 ng/ml hCG bioneutralization capacity; 85%
ofthe 1224 cycles were between 22 and 35 days. Percentage oflonger
and shorter cycles did not differ significantly from those recorded in
women with antibody titers of <35 ng/ml, a level at which women
could conceive in the absence of alternative contraception.
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FIG. 3. Regain of fertility on decline of antibodies. A 30-year-old
subject (STS), with two gravidae and one elective abortion (P2+1), on
immunization with the vaccine, remained protected from pregnancy
for 12 cycles. In the absence of a booster injection, antibody titers
declined and she became pregnant in the cycle starting on day 417.
The extrapolated antibody titers at midcycle in the fertile month,
shown by the dotted line, were <5 ng/ml.
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Table 1. Antibody titers in women who became pregnant
Cycles after
Titer at titers fell to
Subject conception* <50 ng/ml Subject
STS <5 2 NMT
LLA <5 2 PVN
PTB <5 2 STP
GTD <5 4 BLW
URM <5 1 LTA
ANT 10 1 BML
SUN 10 1 RTS
DLY 10 1 BND
SVT 10 2 SRN
RNU 10 1 SRS
RMW 10 2 PVT
BNA 20 2 SNT
MRA 20 1 BNA
Cycles after
Titer at titers fell to
conception* <50 ng/ml
20
20
20
20
24
25
26
30
30
30
30
35
35
1
1
1
1
1
1
1
1
1
1
1
1
1
Subjects becoming pregnant had the choice of continuing pregnancy or seeking its termination.
Twenty-two subjects had the pregnancy terminated, four subjects (GTD, URM, ANT, and NMT)
carried the pregnancy to term and delivered normal babies (three boys, one girl).
*hCG bioneutralization capacity, ng/ml.
effective but those <35 ng/ml are inadequate to prevent preg-
nancy. The effective antibodies have high avidity (Ka 1010
M-1) for hCG. They are partially cross-reactive with human
LH, but this reactivity does not impair ovulation or cause luteal
insufficiency. Nonneutralized LH appears to be sufficient to
induce ovulation even after partial neutralization by antibodies.
This has also been observed in rhesus monkeys immunized with
the (3 subunit ofovine LH (22). The LH cross-reaction does not
cause sufficiently deficient corpus luteum function since men-
strual cycle regularity is maintained.
These observations provide the basis for a possible birth
control vaccine. However, further work is necessary to make
this vaccine workable as a general method for family plan-
ning. The period of =3 months before antibody titers build up
to protective levels in a course ofprimary immunization must
be covered by a compatible companion approach.
The immune response depends on genetic and nutritional
factors. Although the immunogen used in the present vaccine
has several determinants, all recipients of the vaccine do not
generate a high enough antibody response to hCG. In the
present study, 80%o0 of the women produced antibody titers of
>50 ng/ml. Further optimization may be required to enhance
the immune response, such as the use of a better adjuvant.
Encapsulation of the vaccine in microspheres to reduce the
number of injections is also desirable, since the present
schedule involving multiple injections would not be practical
for general use. Such microspheres have been seen to gen-
erate a long-lasting antibody response in experimental ani-
mals after a single administration (23, 24). A live recombinant
vaccine, using vaccinia as the vector, expressing JhCG in
alignment with a transmembrane fragment, has also been
made that generates a high antibody response of long dura-
tion in monkeys (25). This cassette is being transferred to a
fowl pox vector, which expresses the inserted genes but does
not replicate in humans. It remains to be seen whether this
modality of immunization would improve further the anti-
body response.
The present study demonstrates the feasibility of a birth
control vaccine that women could choose on a voluntary
basis. Titers for protection have also been defined. Since
antibody titers decline spontaneously unless booster injec-
tions are given, the duration of effective immunization can be
controlled by the woman herself.
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